NCT02713529 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 42
- group Id
- BG003
- value
- 31
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 117
- units
- Participants
- groups
- description
- Part 1 Cohort 2 includes participants with advanced solid tumors who were treated with 1100 mg AMG 820 plus 200 mg pembrolizumab (Pem) every three weeks (Q3W) to determine safety. Participants could be treated up to 24 months if treatment was tolerable and clinical benefit was observed.
- id
- BG000
- title
- Part 1, Cohort 2: AMG 820 1100 mg + Pem 200 mg
- description
- Part 1 Cohort 1 includes participants with advanced solid tumors who were treated with 1400 mg AMG 820 plus 200 mg pembrolizumab (Pem) every three weeks (Q3W) to determine safety. Participants could be treated up to 24 months if treatment was tolerable and clinical benefit was observed. If \>= 3 participants had dose limiting toxicities (DLTs), a second cohort was created with a lower AMG 820 dose + Pem 200 mg.
- id
- BG001
- title
- Part 1, Cohort 1: AMG 820 1400 mg + Pem 200 mg
- description
- Group 1 is comprised of participants with colorectal cancer (CRC) who are proficient in mismatch repair genes (MMR). AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG002
- title
- Part 2, Group 1: CRC MMR-proficient
- description
- Group 2 is comprised of participants with advanced pancreatic cancer who are naïve to anti programmed-death 1 (PD-1), anti PD-ligand 1 (PD-L1), colony stimulating factor 1 (CSF-1) and colony stimulating factor 1 receptor (CSF-1R) therapies. AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG003
- title
- Part 2, Group 2: Pancreatic Cancer
- description
- Group 3 is comprised of participants with non-small cell lung cancer (NSCLC) who have low (\< 50%) tumor PD-L1- expression and are naïve to anti-PD-1/PD-L1/CSF-1/CSF-1R agents. AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG004
- title
- Part 2, Group 3: NSCLC PD-L1 Low, Naïve
- description
- Group 4a is comprised of participants who did not respond to or who relapsed during monotherapy with anti-PD-1/PD-L1 agents and are anti-CSF-1/CSF-1R naïve. These participants have low PD-L1 tumor expression (\<50%). AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG005
- title
- Part 2, Group 4a: Refractory / Relapsing NSCLC PD-L1 Low
- description
- Group 4b is comprised of participants who did not respond to or who relapsed during monotherapy with anti-PD-1/PD-L1 agents and are anti-CSF-1/CSF-1R naïve. These participants have high PD-L1 tumor expression (\>=50%). AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG006
- title
- Part 2, Group 4b: Refractory/Relapsing NSCLC PD-L1 High
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 64
- title
- 18-64 years
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 41
- title
- 65-74 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 11
- title
- 75-84 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- >=85 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 14
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 43
- title
- Female
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 26
- group Id
- BG003
- value
- 17
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 18
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 74
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 5
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 29
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 108
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 5
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 4
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 39
- group Id
- BG003
- value
- 26
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 17
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 104
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 43
- title
- Grade 0
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 24
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 15
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 74
- title
- Grade 1
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Grade 2
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Grade 3
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Grade 4
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Grade 5
- description
- A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self care, unable to carry out any work activities. Up and about \> 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- 0
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 9
- title
- 1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 35
- title
- 2
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 36
- title
- 3
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 18
- title
- 4
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 19
- title
- 5
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- >5
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of Prior Line of Therapy
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- Stage I
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 9
- title
- Stage II
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 9
- title
- Stage III
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 35
- group Id
- BG003
- value
- 26
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 97
- title
- Stage IV
- description
- There are five stages of cancer: stage 0 (or, carcinoma in situ), stage I, stage II, stage III, and stage IV. Lower stages indicate that the disease is more localized, or contained, whereas higher stages refer to cancers that have spread into other areas of the body.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Disease Stage at Screening
- unit Of Measure
- Participants
- population Description
- All Enrolled Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 42
- group Id
- BG003
- value
- 31
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 117
- units
- Participants
- groups
- description
- Part 1 Cohort 2 includes participants with advanced solid tumors who were treated with 1100 mg AMG 820 plus 200 mg pembrolizumab (Pem) every three weeks (Q3W) to determine safety. Participants could be treated up to 24 months if treatment was tolerable and clinical benefit was observed.
- id
- BG000
- title
- Part 1, Cohort 2: AMG 820 1100 mg + Pem 200 mg
- description
- Part 1 Cohort 1 includes participants with advanced solid tumors who were treated with 1400 mg AMG 820 plus 200 mg pembrolizumab (Pem) every three weeks (Q3W) to determine safety. Participants could be treated up to 24 months if treatment was tolerable and clinical benefit was observed. If \>= 3 participants had dose limiting toxicities (DLTs), a second cohort was created with a lower AMG 820 dose + Pem 200 mg.
- id
- BG001
- title
- Part 1, Cohort 1: AMG 820 1400 mg + Pem 200 mg
- description
- Group 1 is comprised of participants with colorectal cancer (CRC) who are proficient in mismatch repair genes (MMR). AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG002
- title
- Part 2, Group 1: CRC MMR-proficient
- description
- Group 2 is comprised of participants with advanced pancreatic cancer who are naïve to anti programmed-death 1 (PD-1), anti PD-ligand 1 (PD-L1), colony stimulating factor 1 (CSF-1) and colony stimulating factor 1 receptor (CSF-1R) therapies. AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG003
- title
- Part 2, Group 2: Pancreatic Cancer
- description
- Group 3 is comprised of participants with non-small cell lung cancer (NSCLC) who have low (\< 50%) tumor PD-L1- expression and are naïve to anti-PD-1/PD-L1/CSF-1/CSF-1R agents. AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG004
- title
- Part 2, Group 3: NSCLC PD-L1 Low, Naïve
- description
- Group 4a is comprised of participants who did not respond to or who relapsed during monotherapy with anti-PD-1/PD-L1 agents and are anti-CSF-1/CSF-1R naïve. These participants have low PD-L1 tumor expression (\<50%). AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG005
- title
- Part 2, Group 4a: Refractory / Relapsing NSCLC PD-L1 Low
- description
- Group 4b is comprised of participants who did not respond to or who relapsed during monotherapy with anti-PD-1/PD-L1 agents and are anti-CSF-1/CSF-1R naïve. These participants have high PD-L1 tumor expression (\>=50%). AMG 820 was administered at the recommended dose of 1100 mg intravenously in combination with pembrolizumab 200 mg every 3 weeks (± 3 days). Each group in Part 2 was evaluated separately using a Simon 2-stage design. Treatment continued until confirmed disease progression per modified irRECIST, or intolerance of study treatment, or clinically significant deterioration of health status requiring discontinuation, whichever occurred first, or the subject withdrew consent.
- id
- BG006
- title
- Part 2, Group 4b: Refractory/Relapsing NSCLC PD-L1 High
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 64
- title
- 18-64 years
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 41
- title
- 65-74 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 11
- title
- 75-84 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- >=85 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 16
- group Id
- BG003
- value
- 14
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 43
- title
- Female
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 26
- group Id
- BG003
- value
- 17
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 18
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 74
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 5
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 29
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 108
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 5
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 4
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 39
- group Id
- BG003
- value
- 26
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 17
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 104
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 43
- title
- Grade 0
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 24
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 15
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 74
- title
- Grade 1
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Grade 2
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Grade 3
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Grade 4
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Grade 5
- description
- A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self care, unable to carry out any work activities. Up and about \> 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- 0
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 9
- title
- 1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 13
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 35
- title
- 2
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 36
- title
- 3
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 18
- title
- 4
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 19
- title
- 5
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- >5
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Number of Prior Line of Therapy
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- Stage I
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 9
- title
- Stage II
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 9
- title
- Stage III
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 35
- group Id
- BG003
- value
- 26
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 97
- title
- Stage IV
- description
- There are five stages of cancer: stage 0 (or, carcinoma in situ), stage I, stage II, stage III, and stage IV. Lower stages indicate that the disease is more localized, or contained, whereas higher stages refer to cancers that have spread into other areas of the body.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Disease Stage at Screening
- unit Of Measure
- Participants
- population Description
- All Enrolled Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle